The cGAS/STING/IFN-1 Response in Squamous Head and Neck Cancer Cells after Genotoxic Challenges and Abrogation of the ATR-Chk1 and Fanconi Anemia Axis.
ATR
Chk1
Fanconi anemia
STING
cGAS
cisplatin
cytosolic DNA
head and neck cancer
ionizing radiation
type 1 interferons
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
received:
11
09
2023
revised:
28
09
2023
accepted:
29
09
2023
medline:
23
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Locally advanced head and neck squamous cell carcinomas (HNSCC) are often refractory to platinum-based radiochemotherapy and new immuno-oncological strategies. To stimulate immunogenic antitumor responses in HNSCC patients, we investigated the cGAS/STING/IFN-1 signaling pathway after genotoxic treatments and concomitant abrogation of the DNA damage response (DDR). For this purpose, FaDu and UM-SCC1 cells were exposed to X-rays or cisplatin and treated with an ATR or Chk1 inhibitor, or by Fanconi anemia gene A knockout (FANCA ko). We assessed clonogenic survival, cell cycle regulation, micronuclei, free cytosolic double-stranded DNA, and the protein expression and activity of the cGAS/STING/IFN-1 pathway and related players. Cell survival, regulation of G2/M arrest, and formation of rupture-prone cGAS-positive micronuclei after genotoxic treatments were most affected by ATR inhibition and FANCA ko. In UM-SCC-1 cells only, 8 Gy X-rays promoted IFN-1 expression unaltered by abrogation of the DDR or concomitant increased TREX1 expression. At a higher dose of 20 Gy, this effect was observed only for concurrent Chk1- or ATR-inhibition. FANCA ko or cisplatin treatment was ineffective in this regard. Our observations open new perspectives for the enhancement of cGAS/STING/IFN-1-mediated antitumor immune response in HNSCC by hypofractionated or stereotactic radiotherapy concepts in multimodal settings with immuno-oncological strategies.
Identifiants
pubmed: 37834346
pii: ijms241914900
doi: 10.3390/ijms241914900
pmc: PMC10573837
pii:
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Nucleotidyltransferases
EC 2.7.7.-
ATR protein, human
EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
DNA Repair (Amst). 2020 Dec;96:102992
pubmed: 33069004
Nat Commun. 2019 Jan 9;10(1):100
pubmed: 30626869
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Int J Mol Sci. 2021 Feb 03;22(4):
pubmed: 33546122
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
Lancet Oncol. 2021 Apr;22(4):450-462
pubmed: 33794205
Oncotarget. 2017 Dec 11;8(69):114210-114225
pubmed: 29371980
Front Oncol. 2020 Jan 22;9:1522
pubmed: 32039012
Cancer Cell. 2021 Apr 12;39(4):494-508.e5
pubmed: 33545063
Front Oncol. 2019 Mar 19;9:156
pubmed: 30941308
J Clin Invest. 2020 Apr 1;130(4):1635-1652
pubmed: 31874109
J Surg Oncol. 2014 Oct;110(5):551-74
pubmed: 25053506
Cancer. 2017 Oct 15;123(20):3943-3954
pubmed: 28678401
Oncotarget. 2018 Apr 6;9(26):18198-18213
pubmed: 29719599
Haematologica. 2008 Apr;93(4):511-7
pubmed: 18322251
ORL J Otorhinolaryngol Relat Spec. 2007;69(4):218-25
pubmed: 17409780
Ann Oncol. 2023 Jan;34(1):101-110
pubmed: 36522816
EBioMedicine. 2016 Jun;8:184-194
pubmed: 27428429
Acta Otolaryngol. 1996 Mar;116(2):341-4
pubmed: 8725545
Mol Cancer Ther. 2020 Jun;19(6):1279-1288
pubmed: 32371584
EMBO J. 2013 Oct 16;32(20):2751-63
pubmed: 24065129
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
PLoS One. 2017 Nov 14;12(11):e0187532
pubmed: 29135982
Front Immunol. 2021 Jan 28;11:625833
pubmed: 33633744
Front Oncol. 2021 Feb 26;11:623964
pubmed: 33718186
Front Mol Biosci. 2023 Aug 01;10:1148389
pubmed: 37602328
Nat Protoc. 2014 Sep;9(9):2045-60
pubmed: 25079428
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Microbiol Immunol Infect. 2021 Aug;54(4):733-739
pubmed: 32768338
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Nat Rev Clin Oncol. 2023 Aug;20(8):543-557
pubmed: 37280366
Nature. 2017 Aug 24;548(7668):461-465
pubmed: 28738408
DNA Repair (Amst). 2023 Feb;122:103435
pubmed: 36549044
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Front Oncol. 2020 Aug 07;10:1338
pubmed: 32850427
Front Oral Health. 2023 Jul 11;4:1180869
pubmed: 37496754
Expert Rev Mol Med. 2022 Feb 01;24:e8
pubmed: 35101155
Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):106-12
pubmed: 12525204
Int J Cancer. 2023 Jul 1;153(1):183-196
pubmed: 36912284
Nat Rev Genet. 2019 Nov;20(11):657-674
pubmed: 31358977
Mol Cell. 2023 Jan 19;83(2):266-280.e6
pubmed: 36638783
Ann Oncol. 2012 Sep;23 Suppl 10:x173-7
pubmed: 22987957
Oncogenesis. 2019 Jun 17;8(7):38
pubmed: 31209198
Cell Oncol (Dordr). 2022 Feb;45(1):1-18
pubmed: 35015241
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Front Cell Infect Microbiol. 2022 Feb 07;12:820273
pubmed: 35198459
Clin Cancer Res. 2019 Jun 1;25(11):3392-3403
pubmed: 30770349
Cancer Sci. 2019 Nov;110(11):3415-3423
pubmed: 31513320
EMBO J. 2020 Jul 15;39(14):e104036
pubmed: 32484965
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
J Clin Oncol. 2015 Oct 10;33(29):3305-13
pubmed: 26351341
Science. 2015 Oct 30;350(6260):568-71
pubmed: 26405230
Radiother Oncol. 2013 Sep;108(3):495-9
pubmed: 23932155
FEBS J. 2021 Aug;288(15):4507-4540
pubmed: 33529438
Oncotarget. 2017 Jun 16;8(58):97920-97927
pubmed: 29228662
Nature. 2022 Dec;612(7940):495-502
pubmed: 36450981
Annu Rev Cancer Biol. 2019 Mar;3:457-478
pubmed: 30882047
J Clin Oncol. 2017 May 10;35(14):1542-1549
pubmed: 28328302
Microb Pathog. 2019 Jul;132:162-165
pubmed: 31054871
Anticancer Res. 1993 Sep-Oct;13(5A):1405-13
pubmed: 8239512
J Natl Compr Canc Netw. 2017 Jun;15(6):761-770
pubmed: 28596256
Int J Oncol. 2011 Aug;39(2):505-14
pubmed: 21567085
Genes (Basel). 2021 Jun 17;12(6):
pubmed: 34204447
Clin Cancer Res. 2021 Oct 1;27(19):5168-5187
pubmed: 34045293
Cells. 2021 Apr 17;10(4):
pubmed: 33920544
Future Oncol. 2020 Jun;16(18):1235-1243
pubmed: 32490686